MedTrace Logo

A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors

NCT07354711 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2026-01-21

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .

Conditions

Interventions

DRUG

3H-10000

3H-10000 will be administered by infusion Q2W in 28-day cycles.

Sponsors & Collaborators

  • 3H Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-04
Primary Completion
2028-01-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07354711 on ClinicalTrials.gov